Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IMC-002 by ImmuneOncia Therapeutics for Solid Tumor: Likelihood of Approval
IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
IMC-002 by ImmuneOncia Therapeutics for Lymphoma: Likelihood of Approval
IMC-002 is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Lymphoma. According to GlobalData, Phase I...
Danburstotug by ImmuneOncia Therapeutics for Metastatic Melanoma: Likelihood of Approval
Danburstotug is under clinical development by ImmuneOncia Therapeutics and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...